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INTRODUCTION - OBJECTIVE 
 
o Stress-induced hyperglycemia is often experienced in critically ill patients 
  
o Tight Glycemic Control (TGC) can significantly reduce the rate of negative 
outcomes associated with poor control BUT risks of hypoglycemia 
 
o STAR: TGC protocol 
• Flexible 
• Model-based 
• Patient variability 
• Maximum 5% risk of blood glucose (BG) < 90 mg/dL 
 
o Clinical trial objectives: 
→ Safety 
→ Efficacy 
→ Clinical workload minimization 
 
 




o Clinical trial 
• 9 patients 
• 24-hour long 
• 2-3 hourly interventions (BG + insulin) 













Insulin sensitivity (SI) parameter identification (inter-patient variability) 
STEP 1 




o STAR interventions: 3 phases 
 
 BG measurement 
Insulin sensitivity (SI) parameter identification (inter-patient variability) 
Definitions of possible insulin interventions 
STEP 1 
STEP 2 









Insulin sensitivity (SI) parameter identification (inter-patient variability) 
Definitions of possible insulin interventions 
Selection of insulin intervention:  
• Maximum 5% risk of BG < 90 md/dL 
(taking intra-patient variability into account, stochastic model of SI) 








Whole cohort statistics Per-patient statistics (presented as median [IQR]) 
Number of patients: 9 Initial BG (mg/dL): 155.0 [126.5 - 165.0] 
Total hours: 194 hours Hours of control: 23.0 [23.0 - 24.0] 
Number of BG measurements: 91 Number of BG measurements: 11.0 [10.5 - 11.0] 
BG median [IQR] (mg/dL): 134.0 [117.2 - 150.8] BG median (mg/dL): 137.0 [120.3 - 142.4] 
% BG < 100 mg/dL 4.4 Time to < 125 mg/dL (hours): 6.6 [1.9 - 9.0] 
% BG within 100-140 mg/dL 54.9 % patients to < 125 mg/dL: 88.9 
% BG ≥ 140 mg/dL 40.7 Time to < 140 mg/dL (hours): 1.8 [0.0 - 2.6] 
% BG < 40 mg/dL 0.0 % patients to < 140 mg/dL: 100 
Number of patients < 40 mg/dL 0 Median insulin rate (U/hour): 1.4 [0.2 - 2.6] 
Median insulin rate [IQR] (U/hour): 2.0 [1.0 - 2.5] Max insulin rate (U/hour): 3.0 [2.9 - 4.0] 
Median glucose rate [IQR] (g/hour): 0.0 [0.0 - 5.4] Median glucose rate (g/hour): 0.0 [0.0 - 4.7] 







Whole cohort statistics Per-patient statistics (presented as median [IQR]) 
Number of patients: 9 Initial BG (mg/dL): 155.0 [126.5 - 165.0] 
Total hours: 194 hours Hours of control: 23.0 [23.0 - 24.0] 
Number of BG measurements: 91 Number of BG measurements: 11.0 [10.5 - 11.0] 
 
BG median [IQR] (mg/dL): 
 
134.0 [117.2 - 150.8] 
144.0 [118.5-167.0] 
 
BG median (mg/dL): 
 
137.0 [120.3 - 142.4] 
144.0[142.0 – 156.1] 
% BG < 100 mg/dL 4.4 Time to < 125 mg/dL (hours): 6.6 [1.9 - 9.0] 
% BG within 100-140 mg/dL 54.9 % patients to < 125 mg/dL: 88.9 
% BG ≥ 140 mg/dL 40.7 Time to < 140 mg/dL (hours): 1.8 [0.0 - 2.6] 
% BG < 40 mg/dL 0.0 % patients to < 140 mg/dL: 100 
Number of patients < 40 mg/dL 0 Median insulin rate (U/hour): 1.4 [0.2 - 2.6] 
Median insulin rate [IQR] (U/hour): 2.0 [1.0 - 2.5] Max insulin rate (U/hour): 3.0 [2.9 - 4.0] 
Median glucose rate [IQR] (g/hour): 0.0 [0.0 - 5.4] Median glucose rate (g/hour): 0.0 [0.0 - 4.7] 
Pilot trials of STAR Target to Range Glycemic Control 
 
RESULTS 





Whole cohort statistics 
BG median [IQR] (mg/dL): 134.0 [117.2 - 150.8] 







• No BG < 40 mg/dL 
  
→ Efficacy 
• Inter-patient variability 
• Intra-patient variability 
• 54.9% BG within 100-140 mg/dL 
 
→ Clinical workload minimization 









STAR protocol provides tight safe and effective control 
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CONCLUSION 
